All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Should quizartinib maintenance be SOC after SCT for patients with FLT3 mutated AML?
Bookmark this article
During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the AML Global Portal were delighted to speak to Siddhartha Ganguly, The University of Kansas Health System, Kansas City, US. We asked: Should quizartinib maintenance be standard of care after stem cell transplant for patients with FLT3 mutated acute myeloid leukemia?
Siddhartha Ganguly talks about the role of quizartinib in the post and pre-transplant setting. He discusses the results of the QuANTUM-R study that compared quizartinib with salvage chemotherapy in patients with relapsed/ refractory FLT-ITD AML. He also describes his post hoc analysis of that study where he examined the clinical characteristics and the outcome of patients that underwent subsequent allogeneic stem cell transplantation.
Should quizartinib maintenance be SOC after SCT for patients with FLT3 mutated AML?
Your opinion matters
14 votes - 2 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox